# Pizarra — PT-pseudo_3ceacc9b660b (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3ceacc9b660b
Task: 1

Encounter: Urology - outpatient on 23 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 58-year-old male
  - PSA: 6.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.13 ng/mL²
  - PSA velocity: 0.34 ng/mL/yr
  - Prior PSA: 5.4 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7948016 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 6 ng/mL. PI-RADS 3. PSAD 0.13. Prostate volume 49 mL. csPCa 0.79.

Vitals: weight 60 kg, height 178 cm, BMI 18.9, BP 125/74 mmHg, HR 70 bpm. Smoking: Non-smoker.

Chief complaint: Persistent elevation of prostate-specific antigen combined with prior histological confirmation of low-grade malignancy necessitates clinical reassessment.

History: Mr. X is a 58-year-old retired mechanical engineer who lives in a multi-generational home with his spouse and adult daughter. A non-smoker, he maintains an alcohol-free lifestyle and performs chair-based exercises to accommodate limited mobility. Urinary complaints are minimal, scoring 2 out of 35 on the IPSS. His medical background includes hypertension, currently managed with amlodipine, lisinopril, and metoprolol. Additional historical points feature a stable HbA1c of 6.4%, a remote appendectomy during his thirties, and a recent vascular surgery consultation for varicose veins, with no accompanying systemic complaints or bone pain.

Physical examination: DRE: The prostate exhibits a symmetric enlargement characterized by a smooth, firm consistency. Palpation identifies no nodules or asymmetrical areas. General survey shows stable vital signs, an unremarkable abdominal exam, and no palpable lymphadenopathy.

Patient info: retired mechanical engineer; Married; Lives with adult child (multi-generational household).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Limited mobility — chair-based exercises only; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.43 +/- 0.19   (95% CI 0.10-0.81)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.4 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=3.0, bx_ord=3.0, psa=6.0, age=58.0, psad=0.13, dre_ord=0.0, vol=49.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the PSA velocity (0.34 ng/mL/yr), the PSA trend (prior PSA 5.4 ng/mL), or the full laboratory panel, which are crucial for assessing the rate of change and overall health context.
  The prior could not weigh the specific details of the mpMRI report prose (beyond the PI-RADS 3 score) or the specific findings in the previous notes, which might contradict the PI-RADS score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.43 +/- 0.19), indicating high uncertainty. This uncertainty is likely due to the lack of context regarding the PSA velocity (0.34 ng/mL/yr) and the prior positive biopsy status.
  A failure mode is ignoring the prior positive biopsy status; if the prior positive result implies a specific low-grade diagnosis, the current PI-RADS 3 and rising PSA might be managed differently than if the prior was negative.
  Another failure mode is the high csPCa predicted probability (0.7948016) being potentially misleading if the DRE is normal and the PI-RADS is only 3, suggesting the prior's reliance on the structured data over clinical context is flawed.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> What are the specific findings in the mpMRI prose? -> Specific findings could confirm or refute the PI-RADS 3 score.
  <document> PSA history (trend) -> What is the full PSA trajectory? -> The velocity (0.34 ng/mL/yr) is critical for risk stratification.
  <document> previous GP / urology consultation notes -> What were the specific clinical concerns or management plans? -> Context on the prior positive biopsy and current clinical management.
  <document> laboratory results (full panel) -> What are the full lab results? -> To check for other markers that might influence the decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_3ceacc9b660b", "radiology_report": "Erasmus MC University Medical Center | 15 Feb 2025 | Multiparametric MRI Prostate\n\nClinical context involves an elevated PSA reading of 6.0 alongside a previously positive biopsy and a PI-RADS 3 designation on earlier imaging.\n\nProstate dimensions total 49.0 mL. T2 sequences highlight a 12 mm hypointense focus within the right mid-gland peripheral zone. Diffusion-weighted sequences exhibit moderately restricted diffusion paired with low ADC values, falling short of definitive malignancy. Contrast-enhanced phases reveal early, equivocal uptake in the lesion. Seminal vesicles appear normal; extracapsular extension and suspicious lymphadenopathy are absent.\n\nPI-RADS 3. PSAD 0.13. csPCa predicted probability 0.7948016."}

  **psa_trend**
  {"case_id": "PT-pseudo_3ceacc9b660b", "psa_trend": [{"date": "Dec 2023", "val": 1.2}, {"date": "Apr 2024", "val": 2.1}, {"date": "Sep 2024", "val": 3.5}, {"date": "Feb 2025", "val": 6.0}]}

  **previous_notes**
  {"case_id": "PT-pseudo_3ceacc9b660b", "previous_notes": [{"date": "26 Oct 2024", "author": "Dr. R. van den Berg (GP)", "text": "26 Oct 2024 - Dr. R. van den Berg (GP): PSA climbed to 5.4 ng/mL after a plateau, triggering a urology referral for re-assessment given the earlier positive biopsy. Urinary symptoms remain absent, and routine laboratory panels stay within acceptable ranges."}, {"date": "29 Feb 2024", "author": "Dr. R. van den Berg (GP)", "text": "29 Feb 2024 - Dr. R. van den Berg (GP): A PSA measurement of 4.8 ng/mL indicated a slight quarterly decline. Lower urinary tract symptoms are absent, and the antihypertensive medication course continues without adverse effects."}]}

  **lab_results**
  {"case_id": "PT-pseudo_3ceacc9b660b", "laboratory_results": [{"name": "PSA", "val": "6.0 ng/mL", "date": "07 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.44 ng/mL", "date": "07 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "24%", "date": "07 Feb 2025", "flag": ""}, {"name": "Haemoglobin", "val": "16.0 g/dL", "date": "07 Feb 2025", "flag": ""}, {"name": "WBC", "val": "7.9 x10^9/L", "date": "07 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "185 x10^9/L", "date": "07 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "90 umol/L", "date": "07 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "07 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "11.7 nmol/L", "date": "07 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "99 U/L", "date": "07 Feb 2025", "flag": ""}, {"name": "LDH", "val": "191 U/L", "date": "07 Feb 2025", "flag": ""}, {"name": "HbA1c", "val": "6.4 %", "date": "07 Feb 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy prioritized the other documents which directly address the gaps identified by LLM-1-GAP-ANALYST.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PSA velocity of 0.34 ng/mL/yr, indicating a rising trend.
  - PI-RADS 3 score on MRI, suggesting equivocal findings that warrant further investigation given the clinical context.
  - Prior positive biopsy result, necessitating re-evaluation.

  AGAINST sampling this patient now:
  - DRE findings are Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
  - MRI findings show "moderately restricted diffusion paired with low ADC values, falling short of definitive malignancy."

WHERE THIS LEANS
  The evidence suggests a need for further investigation due to the rising PSA and equivocal MRI findings (PI-RADS 3), which contradicts the statistical prior of 'NO BIOPSY'. This leans towards considering a biopsy to clarify the equivocal MRI findings and the rising PSA trajectory.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the patient has a prior positive biopsy, necessitating re-evaluation, and the evidence shows a rising PSA velocity of 0.34 ng/mL/yr. This is supported by the PI-RADS 3 finding on MRI and the PSA density of 0.13 ng/mL², which, combined with the rising PSA trend, warrants further tissue clarification. The statistical prior suggesting no biopsy was overturned by the clinical evidence pointing toward a need for investigation.

Variables that carried weight: bx=decisive, dre=noted, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
